Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial 18 December
Updated data for Lilly's Inluriyo reinforce efficacy results as monotherapy and in combination with Verzenio® in ER+, HER2- advanced breast cancer 12 December
